Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Cash & Equivalents (2023 - 2025)

Metagenomi (MGX) has disclosed Cash & Equivalents for 3 consecutive years, with $41.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 52.35% to $41.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.7 million, a 52.35% increase, with the full-year FY2025 number at $41.7 million, up 52.35% from a year prior.
  • Cash & Equivalents was $41.7 million for Q4 2025 at Metagenomi, up from $32.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $140.6 million in Q4 2023 to a low of $25.1 million in Q3 2024.
  • A 3-year average of $61.4 million and a median of $46.7 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 80.52% in 2024, then skyrocketed 52.35% in 2025.
  • Metagenomi's Cash & Equivalents stood at $140.6 million in 2023, then crashed by 80.52% to $27.4 million in 2024, then surged by 52.35% to $41.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Cash & Equivalents are $41.7 million (Q4 2025), $32.8 million (Q3 2025), and $26.8 million (Q2 2025).